Bullboard - Stock Discussion Forum Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and... see more

Add To Watchlist

OTCPK:RGBP - Post Discussion

Regen BioPharma Inc > Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Pro

View:

Post by Tdogzz18 on Nov 14, 2023 9:58am

Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Pro

SAN DIEGO, Nov. 14, 2023

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html). This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6. As part of the development of this program, it was discovered that NR2F6 mRNA was greatly increased, thus identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.

The Company is now preparing a series of in vitro experiments to determine if these DuraCAR cells are indeed immunosuppressive, rather than possessing anti-tumor activity as originally envisioned.

https://www.marketwatch.com/press-release/regen-biopharma-inc-ceo-outlines-future-steps-in-car-t-program-9509d381?mod=mw_quote_news_seemore